vs
Ginkgo Bioworks Holdings, Inc.（DNA）与HomeTrust Bancshares, Inc.（HTB）财务数据对比。点击上方公司名可切换其他公司
HomeTrust Bancshares, Inc.的季度营收约是Ginkgo Bioworks Holdings, Inc.的1.6倍（$53.6M vs $33.4M），HomeTrust Bancshares, Inc.同比增速更快（3.7% vs -23.8%），HomeTrust Bancshares, Inc.自由现金流更多（$45.3M vs $-47.7M），过去两年HomeTrust Bancshares, Inc.的营收复合增速更高（3.5% vs -6.2%）
Ginkgo Bioworks Holdings, Inc.是一家2008年由五名麻省理工学院科学家创立的美国生物技术企业，由杰森·凯利掌舵。公司专注于基因工程改造，为其他生物科技企业开发具备工业应用价值的菌株，帮助合作方省去合成生物学设计初期的重复研发成本，号称「生物制造平台企业」，2019年估值就已达42亿美元。
HomeTrust Bancshares, Inc.是总部位于美国北卡罗来纳州阿什维尔的银行控股公司，总资产达43亿美元，在北卡、南卡、佐治亚和田纳西州共设有33家网点，旗下拥有HomeTrust银行、Tryon联邦银行等七家社区银行。
DNA vs HTB — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $33.4M | $53.6M |
| 净利润 | — | — |
| 毛利率 | — | — |
| 营业利润率 | -211.9% | 37.0% |
| 净利率 | — | — |
| 营收同比 | -23.8% | 3.7% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $-1.41 | $0.93 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $33.4M | $53.6M | ||
| Q3 25 | $38.8M | $54.1M | ||
| Q2 25 | $49.6M | $54.4M | ||
| Q1 25 | $48.3M | $50.9M | ||
| Q4 24 | $43.8M | $51.7M | ||
| Q3 24 | $89.0M | $50.6M | ||
| Q2 24 | $56.2M | $50.6M | ||
| Q1 24 | $37.9M | $50.0M |
| Q4 25 | — | — | ||
| Q3 25 | $-80.8M | $16.5M | ||
| Q2 25 | $-60.3M | $17.2M | ||
| Q1 25 | $-91.0M | $14.5M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-56.4M | $13.1M | ||
| Q2 24 | $-217.2M | $12.4M | ||
| Q1 24 | $-165.9M | $15.1M |
| Q4 25 | -211.9% | 37.0% | ||
| Q3 25 | -231.8% | 38.5% | ||
| Q2 25 | -132.1% | 40.1% | ||
| Q1 25 | -184.1% | 36.2% | ||
| Q4 24 | -236.3% | 35.4% | ||
| Q3 24 | -62.0% | 33.2% | ||
| Q2 24 | -396.7% | 31.3% | ||
| Q1 24 | -469.1% | 38.0% |
| Q4 25 | — | — | ||
| Q3 25 | -207.9% | 30.5% | ||
| Q2 25 | -121.6% | 31.6% | ||
| Q1 25 | -188.2% | 28.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | -63.3% | 25.9% | ||
| Q2 24 | -386.4% | 24.6% | ||
| Q1 24 | -437.3% | 30.1% |
| Q4 25 | $-1.41 | $0.93 | ||
| Q3 25 | $-1.45 | $0.95 | ||
| Q2 25 | $-1.10 | $1.00 | ||
| Q1 25 | $-1.68 | $0.84 | ||
| Q4 24 | $-1.91 | $0.83 | ||
| Q3 24 | $-1.08 | $0.76 | ||
| Q2 24 | $-4.23 | $0.73 | ||
| Q1 24 | $-3.32 | $0.88 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $422.6M | $324.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $508.6M | $600.7M |
| 总资产 | $1.1B | $4.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $422.6M | $324.7M | ||
| Q3 25 | $495.5M | $315.8M | ||
| Q2 25 | $559.4M | $297.2M | ||
| Q1 25 | $325.3M | $299.8M | ||
| Q4 24 | $561.6M | $279.2M | ||
| Q3 24 | $616.2M | $293.5M | ||
| Q2 24 | $730.4M | $294.2M | ||
| Q1 24 | $840.4M | $380.5M |
| Q4 25 | $508.6M | $600.7M | ||
| Q3 25 | $559.8M | $595.8M | ||
| Q2 25 | $613.0M | $579.3M | ||
| Q1 25 | $647.4M | $565.4M | ||
| Q4 24 | $716.1M | $551.8M | ||
| Q3 24 | $797.9M | $540.0M | ||
| Q2 24 | $833.1M | $523.6M | ||
| Q1 24 | $987.3M | $513.2M |
| Q4 25 | $1.1B | $4.5B | ||
| Q3 25 | $1.2B | $4.6B | ||
| Q2 25 | $1.2B | $4.6B | ||
| Q1 25 | $1.3B | $4.6B | ||
| Q4 24 | $1.4B | $4.6B | ||
| Q3 24 | $1.5B | $4.6B | ||
| Q2 24 | $1.6B | $4.7B | ||
| Q1 24 | $1.6B | $4.7B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-47.7M | $49.5M |
| 自由现金流经营现金流 - 资本支出 | $-47.7M | $45.3M |
| 自由现金流率自由现金流/营收 | -142.8% | 84.5% |
| 资本支出强度资本支出/营收 | 0.0% | 7.8% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $93.8M |
8季度趋势，按日历期对齐
| Q4 25 | $-47.7M | $49.5M | ||
| Q3 25 | $-31.6M | $-11.3M | ||
| Q2 25 | $-40.3M | $-8.8M | ||
| Q1 25 | $-51.5M | $71.7M | ||
| Q4 24 | $-42.4M | $45.4M | ||
| Q3 24 | $-103.5M | $43.8M | ||
| Q2 24 | $-84.4M | $5.9M | ||
| Q1 24 | $-89.3M | $-9.0M |
| Q4 25 | $-47.7M | $45.3M | ||
| Q3 25 | — | $-12.0M | ||
| Q2 25 | $-40.3M | $-10.2M | ||
| Q1 25 | $-59.1M | $70.7M | ||
| Q4 24 | $-56.1M | $42.4M | ||
| Q3 24 | $-118.6M | $43.1M | ||
| Q2 24 | $-111.4M | $5.7M | ||
| Q1 24 | $-96.0M | $-9.6M |
| Q4 25 | -142.8% | 84.5% | ||
| Q3 25 | — | -22.2% | ||
| Q2 25 | -81.2% | -18.7% | ||
| Q1 25 | -122.4% | 138.7% | ||
| Q4 24 | -128.0% | 82.0% | ||
| Q3 24 | -133.2% | 85.1% | ||
| Q2 24 | -198.2% | 11.2% | ||
| Q1 24 | -252.9% | -19.2% |
| Q4 25 | 0.0% | 7.8% | ||
| Q3 25 | 0.0% | 1.4% | ||
| Q2 25 | 0.1% | 2.5% | ||
| Q1 25 | 15.8% | 2.0% | ||
| Q4 24 | 31.3% | 5.9% | ||
| Q3 24 | 16.9% | 1.3% | ||
| Q2 24 | 48.1% | 0.5% | ||
| Q1 24 | 17.7% | 1.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | -0.68× | ||
| Q2 25 | — | -0.51× | ||
| Q1 25 | — | 4.93× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 3.34× | ||
| Q2 24 | — | 0.48× | ||
| Q1 24 | — | -0.60× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DNA
| Cell Engineering Segment | $26.0M | 78% |
| Other | $7.4M | 22% |
HTB
暂无分部数据
